ONCT
- Oncternal Therapeutics, Inc.
()
Overview
Company Summary
Oncternal Therapeutics, Inc. (ONCT) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer. The company specializes in harnessing the power of targeted protein-coding genes, known as tumor suppressor genes, to develop potential therapies for various types of cancer.
One of the key areas of focus for Oncternal Therapeutics is developing small molecule drug candidates and monoclonal antibodies. These drug candidates are designed to address specific molecular targets in cancer cells, which are often associated with the abnormal growth and proliferation of cancer cells.
The company's pipeline includes several investigational drugs at various stages of development. These drugs target specific cancer types such as lymphoma, leukemia, and solid tumors. Oncternal Therapeutics is conducting clinical trials to evaluate the safety and efficacy of these drugs, with the ultimate goal of obtaining regulatory approvals and making them available to patients.
Additionally, Oncternal Therapeutics collaborates with academic and research institutions, as well as other biopharmaceutical companies, to further advance its technology and drug development efforts. By working in partnership with key stakeholders, the company aims to accelerate the discovery and development of new therapies for patients with limited treatment options.
Overall, Oncternal Therapeutics is dedicated to advancing the fight against cancer by leveraging its expertise in tumor suppressor genes and targeted therapies. Through its innovative approach and collaborative efforts, the company aims to make a positive impact on the lives of patients affected by cancer.